PMA supplement
P120016 S037: Cardiva VASCADE MVP XL Venous Vascular Closure System (VVCS)
FDA PMA supplement · 30-Day Notice · Cardiva Medical, Inc.
Key facts
| Original PMA | P120016 |
|---|---|
| Supplement number | S037 |
| Supplement type | 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | Cardiva VASCADE MVP XL Venous Vascular Closure System (VVCS) |
| Generic name | Device, hemostasis, vascular |
| Applicant | Cardiva Medical, Inc. |
| Product code | MGB |
| Received date | Oct 21, 2024 |
| Decision date | Nov 19, 2024 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: